Click to make ImmunologyLink your homepage
The Immunology Link
FDA  Approved Antibody-based Therapeutics
Name:
Antibody
Target:
Antibody Type
Indication Company Approval Date
*OKT3:
Muronomab-CD3
CD3:
Murine, IgG2a
Autoimmune Johnson & Johnson 1986 (US)
ReoPro:
Abciximab
PIIb/IIIa:
Chimeric, IgG1, Fab
Homeostasis Johnson & Johnson 1984 (US)
Rituxan:
Rituximab
CD20:
Chimeric, IgG1
Cancer Genentech 1997 (US)
1998 (EU)
*Zenapax:
Daclizumab
CD25:
Humanized, IgG1
Autoimmune Roche 1997 (US)
1999 (EU)
Simulect:
Basiliximab
CD25:
Chimeric, IgG1
Autoimmune Novartis 1998  (US)
1998 (EU)
Synagis:
Palivizumab
RSV:
Humanized, IgG1
Infections MedImmune 1998 (US)
1999 (EU)
Remicade:
Infliximab
TNFa:
Chimeric, IgG1
Autoimmune Johnson & Johnson 1998 (US)
1999 (EU)
Herceptin:
Trastuzumab
HER2:
Humanized, IgG1
Cancer Genentech/
Roche
1998 (US)
2000 (EU)
*Mylotarg:
Gemtuzumab ozogamicin
CD33:
Humanized, IgG4, immunotoxin
Cancer Wyeth/
Pfizer
2000 (US)
Campath:
Alemtuzumab
CD52:
Humanized, IgG1
Cancer Genzyme 2001 (US)
2001 (EU)
Zevalin:
Ibritumomab tiuxetan
CD20:
Murine, IgG1, radiolabeled (Yttrium 90)
Cancer Biogen Idec 2002 (US)
2004 (EU)
Humira:
Adalimumab
TNFa:
Human, IgG1
Autoimmune Abbott 2002 (US)
2003 (EU)
Xolair:
Omalizumab
IgE:
Humanized, IgG1
Autoimmune Genentech/
Roche
2003 (US)
Bexxar:
Tositumomab-I-131
CD20:
Murine, IgG2a, radiolabeled (Iodine 131)
Cancer Corixa/GSK 2003 (US)
*Raptiva:
Efalizumab
CD11a:
Humanized, IgG1
Autoimmune Genentech/
Roche
2003 (US)
2004 (EU)
Erbitux:
Cetuximab
EGFR:
Chimeric, IgG1
Cancer Imclone/
Lilly
2004 (US)
2004 (EU)
Avastin:
Bevacizumab
VEGF:
Humanized, IgG1
Cancer Genentech/
Roche
2004 (US)
2005 (EU)
Tysabri:
Natalizumab
a4-Intergrin:
Humanized, IgG4
Autoimmune Biogen Idec 2004 (US)
Actemra:
Tocilizumab
Anti-IL-6R:
Humanized, IgG1
Autoimmune Chugai/
Roche
2005
(JP)
2010 (US)
Vectibix:
Panitumumab
EGFR:
Human, IgG2
Cancer Amgen 2006 (US)
Lucentis: Ranibizumab VEGF: Humanized IgG1 Fab Macular degeneration Genentech/
Roche
2006
(US)
Soliris:
Eculizumab
C5:
Humanized IgG2/4
Blood disorders Alexion 2007 (US)
Cimzia:
Certolizumab
pegol
TNFa:
Humanized, pegylated Fab
Autoimmune UCB 2008 (US)
Simponi:
Golimumab
TNFa: Human IgG1 Autoimmune Johnson & Johnson 2009
(US, EU, CAN)
Ilaris:
Canakinumab 
IL1b:
Human IgG1
Infalmmatory  Novartis 2009
(US,EU)
Stelara:
Ustekinumab   
IL-12/23: Human IgG1 Autoimmune Johnson & Johnson 2009
(US)
2008
(EU)
Arzerra:
Ofatumumab 
CD20: Human IgG1  Cancer Genmab 2009
(EU)
Prolia:
Denosumab   
RANK ligand: Human IgG2 Bone Loss Amgen 2010
(US)
Numax:
Motavizumab  
RSV: Humanized IgG1 Anti-infective Meddimmune Pending
ABThrax:
Raxibacumab   
B. anthrasis PA:
 Human IgG1
Anti-infection GSK 2012
(US)
Benlysta:
Belimumab   
BLyS: Human IgG1 Autoimmune Human Genome Sciences 2011
(US)
Yervoy:
Ipilimumab
CTLA-4:  Human IgG1  Cancer BMS 2011
(US)
Adcetris:
Brentuximab Vedotin
CD30:  Chimeric, IgG1, Drug-conjugate  Cancer Seattle Genetics 2011
(US)
Perjeta:
Pertuzumab
Her2:  Humanized, IgG1 Cancer Genentech/
Roche
2012
(US)
Kadcyla:
Ado-trastuzumab emtansine
Her2:  Humanized, IgG1, Drug-conjugate Cancer Genentech/
Roche
2013
(US)
Gazyva:
Obinutuzumab
CD20: 

humanized and glyco-engineered

Cancer Genentech/
Roche
2013
(US)
  *Withdrawn by the sponsor
Other antibodies in trials
 
FDA-Approved Drugs (ALL)
Drugs approved by the Food and Drug Administration (FDA) for sale in the United States